Influence of the dietary supplement taurine on the cardiovascular system in chronic heart failure

Influence of the dietary supplement taurine on the cardiovascular system in chronic heart failure - HFpEF-TS

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00037123

Enrollment

Registered

2025-06-23

Start date

2026-03-01

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I50

Interventions

Group 1: 6g taurine / day (orally) Group 2: placebo (orally)

Eligibility

Sex/Gender

All

Age

50 Years to No maximum

Inclusion criteria

Inclusion criteria: Disease definition according to established guidelines: HFpEF is defined as a sign and symptom of heart failure with a left ventricular ejection fraction of =50%

Exclusion criteria

Exclusion criteria: • Refusal to participate in the study • Lack of capacity to consent • Cardiovascular event less than 6 months ago • Active malignant diseases • Persons with cardiac pacemakers • Taurine supplementation in the last 3 months

Design outcomes

Primary

Measure	Time frame
Flow-mediated vasodilation (FMD, µm/%) of the brachial artery, measured with UNEX EF 38G before and after treatment	—

Secondary

Measure	Time frame
Secondary endpoints (before and after treatment): - Reactive hyperemia index (RHI), measured by plethysmography on the index finger using EndoPat 2000 - Diastolic cardiac function and global strain of the left atrium and left ventricle, measured by echocardiography - Systolic function and atrial size, measured by echocardiography - Intima-media thickness (mm), measured by Doppler duplex ultrasonography - Maximum oxygen uptake (VO2max), performance (watts), and exercise duration, measured using spiroergometry - 14-day activity profile with step count, activity intensity, sleep duration, and energy consumption (activity counts), measured using actigraphy - Heart rate (bmp), as well as systolic, diastolic and mean arterial blood pressure (mmHg), measured once using Philips EarlyVue VS30 vital signs monitor and measured over 24 h using ABPMpro for day and night mean values - PWV (m/s), measured once with PulsePen and over 24 h using ABPMpro for day and night mean values - NT-proBNP (ng/l), troponin values (ng/l), CRP (mg/dl), glucose (mg/dl) and HbA1c (%), triglycerides (mg/dl), HDL-/LDL-/ total cholesterol (mg/dl), taurin (µmol/l) measured in blood (fasting) - Creatinine (mg/dl), measured in spontaneous urine - Cardiopulmonary endurance, measured as walking distance in the 6-minute walk test (m) - Hand grip strength (kg), measured with dynamometer - Total body water, fat mass, fat-free mass, phase angle, resistance and reactance, measured using bioimpedance analysis and air displacement plethysmography - 24 h blood glucose profile and response to oral glucose tolerance test (mmol/l), measured by blood glucose sensor - Retinal vessel density (ONH perfusion, %), measured using optical coherence tomography (OCT-A) - Pathological changes in the peripheral retina, such as hemorrhages, exudates or vascular anomalies, detected by funduscopy - Dilatation capacity of retinal vessels (%) when stimulated with flicker light, measured with Dynamic Vessel Analyzer	—

Measure

Time frame

Secondary endpoints (before and after treatment): - Reactive hyperemia index (RHI), measured by plethysmography on the index finger using EndoPat 2000 - Diastolic cardiac function and global strain of the left atrium and left ventricle, measured by echocardiography - Systolic function and atrial size, measured by echocardiography - Intima-media thickness (mm), measured by Doppler duplex ultrasonography - Maximum oxygen uptake (VO2max), performance (watts), and exercise duration, measured using spiroergometry - 14-day activity profile with step count, activity intensity, sleep duration, and energy consumption (activity counts), measured using actigraphy - Heart rate (bmp), as well as systolic, diastolic and mean arterial blood pressure (mmHg), measured once using Philips EarlyVue VS30 vital signs monitor and measured over 24 h using ABPMpro for day and night mean values - PWV (m/s), measured once with PulsePen and over 24 h using ABPMpro for day and night mean values - NT-proBNP (ng/l), troponin values (ng/l), CRP (mg/dl), glucose (mg/dl) and HbA1c (%), triglycerides (mg/dl), HDL-/LDL-/ total cholesterol (mg/dl), taurin (µmol/l) measured in blood (fasting) - Creatinine (mg/dl), measured in spontaneous urine - Cardiopulmonary endurance, measured as walking distance in the 6-minute walk test (m) - Hand grip strength (kg), measured with dynamometer - Total body water, fat mass, fat-free mass, phase angle, resistance and reactance, measured using bioimpedance analysis and air displacement plethysmography - 24 h blood glucose profile and response to oral glucose tolerance test (mmol/l), measured by blood glucose sensor - Retinal vessel density (ONH perfusion, %), measured using optical coherence tomography (OCT-A) - Pathological changes in the peripheral retina, such as hemorrhages, exudates or vascular anomalies, detected by funduscopy - Dilatation capacity of retinal vessels (%) when stimulated with flicker light, measured with Dynamic Vessel Analyzer

—

Countries

Germany

Contacts

Public ContactKristin Kräker

Charité Universitätsmedizin Berlin

kristin.kraeker@charite.de+49 30 450540 328

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 7, 2026